Thursday, 17 October 2019

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

09 July 2019 | News

It is a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million.

Glenmark’s current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the USFDA.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Asia-Pacific dominating the global digital transformation in healthcare market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls